(Vavantor Q3 2024 Earnings EARNINGS PRESENTATION October 25, 2024 AVTR LISTED NYSE Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking ...

Avantor, Inc. (AVTR) reported third-quarter 2024 adjusted earnings per share (EPS) of 26 cents, up by a penny from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 4%. GAAP EPS for the quarter was 8 cents, down 50% year over year. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. AVTR Revenue Details Revenues grossed $1.71 billion in the reported quarter, down 0.3% year over year. The metric missed the Zacks Consensus Estimate by 0.6%. Per management, the ...

Avantor Inc. (NYSE:AVTR) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President and Chief Executive Officer Brent Jones - Executive Vice President and Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Daniel Leonard - UBS Conor McNamara - RBC Capital Markets Daniel Arias - Sti ...

Avantor, Inc. (AVTR) reported $1.71 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.3%. EPS of $0.26 for the same period compares to $0.25 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.72 billion, representing a surprise of -0.57%. The company delivered an EPS surprise of +4.00%, with the consensus EPS estimate being $0.25.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ━━━━━━━━━ FORM 10-Q ━━━━━━━━━ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38912 Avantor, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2758923 ...

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4%. A quarter ago, it was expected that this company would post earnings of $0.23 per share when it actually produced earnings of $0.25, delivering a surprise of 8.70%.Over the last four quarters, the company has sur ...

Exhibit 99.1 Avantor® Reports Third Quarter 2024 Results • Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% • Net income of $57.8 million; Adjusted EBITDA of $302.5 million • Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 • Operating cash flow of $244.8 million; free cash flow of $204.0 million RADNOR, Pa. – October 25, 2024 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology indust ...

Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fi ...

Avantor and NIBRT have formed a new partnership to supply advanced Masterflex® equipment, essential products, and expert training to foster innovations in biopharma manufacturing RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced an expanded partnership with the National Institute for Bioprocessing Research and Training (NIBRT). The new ...

Transaction Details - Avantor Inc (AVTR) closed the divestiture of its clinical services business to Audax Private Equity for approximately $650 million [1] - The deal includes kitting, biorepository, and related equipment and ancillaries, collectively known as Clinical Services [3] - The transaction is expected to generate approximately $500 million in after-tax cash proceeds and reduce approximately $50 million in capitalized leases [3] Financial Impact - The divestiture strengthens AVTR's balance sheet and reduces interest expenses [1] - Management plans to use the after-tax proceeds for debt paydown [3] - The deal aligns with AVTR's new operating model and accelerates its business transformation [3] Stock Performance - AVTR shares closed flat at $24.73 following the announcement [2] - Year-to-date, AVTR shares have rallied 8.3%, outperforming the industry's decline of 2.5% [2] - The S&P 500 increased 22.9% during the same period [2] Industry Prospects - The global analytical laboratory service market is estimated to be $472.6 million in 2024 and projected to reach $1,375 million by 2034, growing at a CAGR of 11.3% [4] - Factors driving the market include the growing popularity of point-of-care testing and the adoption of smart lab infrastructure with sensor networks [5] - The divestiture is expected to provide significant impetus to AVTR's lab and production businesses [5] Comparative Stock Analysis - AVTR currently carries a Zacks Rank 3 (Hold) [6] - Better-ranked stocks in the medical space include Boston Scientific (BSX), DaVita (DVA), and Masimo (MASI), each with a Zacks Rank 2 (Buy) [6] - Boston Scientific shares have gained 70.4% in the past year, with EPS estimates remaining constant at $2.40 for 2024 and $2.71 for 2025 [6] - DaVita shares have surged 103.3% in the past year, with 2024 EPS estimates remaining constant at $9.99 [7] - Masimo shares have surged 80.4% in the past year, with 2024 EPS estimates rising 0.3% in the past 30 days [7]